JP7545979B2 - ＵＤＰグリコシルトランスフェラーゼ阻害剤としてのチエノ［３，２－ｂ］ピリジン誘導体および使用の方法 - Google Patents

ＵＤＰグリコシルトランスフェラーゼ阻害剤としてのチエノ［３，２－ｂ］ピリジン誘導体および使用の方法 Download PDF

Info

Publication number
JP7545979B2
JP7545979B2 JP2021542086A JP2021542086A JP7545979B2 JP 7545979 B2 JP7545979 B2 JP 7545979B2 JP 2021542086 A JP2021542086 A JP 2021542086A JP 2021542086 A JP2021542086 A JP 2021542086A JP 7545979 B2 JP7545979 B2 JP 7545979B2
Authority
JP
Japan
Prior art keywords
thieno
trifluoromethyl
pyridin
methylcarbamoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021542086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508523A (ja
JP2022508523A5 (https=
JPWO2020072504A5 (https=
Inventor
サングターク・リム
ロバート・エイチ・バーカー・ジュニア
マリー・エー・クロムウェル
エリナ・マキノ
ブラッドフォード・ハース
ジョン・ジアン
サチン・マニアー
マーク・マンソン
ヨン－ミ・チョイ
スカンティニ・スレイラトナム
クウォン・ヨン・ムシック
ジェームズ・プリビッシュ
マイケル・アンジェラストロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2022508523A publication Critical patent/JP2022508523A/ja
Publication of JP2022508523A5 publication Critical patent/JP2022508523A5/ja
Publication of JPWO2020072504A5 publication Critical patent/JPWO2020072504A5/ja
Application granted granted Critical
Publication of JP7545979B2 publication Critical patent/JP7545979B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021542086A 2018-10-01 2019-10-01 ＵＤＰグリコシルトランスフェラーゼ阻害剤としてのチエノ［３，２－ｂ］ピリジン誘導体および使用の方法 Active JP7545979B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
US62/739,405 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (4)

Publication Number Publication Date
JP2022508523A JP2022508523A (ja) 2022-01-19
JP2022508523A5 JP2022508523A5 (https=) 2022-09-07
JPWO2020072504A5 JPWO2020072504A5 (https=) 2022-09-07
JP7545979B2 true JP7545979B2 (ja) 2024-09-05

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542086A Active JP7545979B2 (ja) 2018-10-01 2019-10-01 ＵＤＰグリコシルトランスフェラーゼ阻害剤としてのチエノ［３，２－ｂ］ピリジン誘導体および使用の方法

Country Status (15)

Country Link
US (1) US11098056B2 (https=)
EP (1) EP3861000A1 (https=)
JP (1) JP7545979B2 (https=)
KR (1) KR102903997B1 (https=)
CN (1) CN113423711B (https=)
AU (1) AU2019355870B2 (https=)
BR (1) BR112021005914A2 (https=)
CA (1) CA3114722A1 (https=)
CO (1) CO2021005738A2 (https=)
IL (1) IL281811B2 (https=)
MA (1) MA53043B2 (https=)
MX (1) MX2021003794A (https=)
SG (1) SG11202102987VA (https=)
TW (1) TWI821426B (https=)
WO (1) WO2020072504A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302565A (zh) * 2021-02-19 2023-01-16 英商卡爾維斯塔製藥有限公司 酶抑制劑
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528810A (ja) 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク メラノコルチン−４受容体結合化合物及びその使用方法
JP2011503115A (ja) 2007-11-15 2011-01-27 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Ｎ含有複素環式化合物
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
MX2011008276A (es) * 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
ES2928714T3 (es) * 2015-01-16 2022-11-22 Massachusetts Gen Hospital Compuestos para mejorar el empalme del ARNm
WO2017214505A1 (en) * 2016-06-10 2017-12-14 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
MY193511A (en) * 2016-11-02 2022-10-17 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
EP3619209A1 (en) * 2017-05-04 2020-03-11 Glenmark Pharmaceuticals S.A. Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528810A (ja) 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク メラノコルチン−４受容体結合化合物及びその使用方法
JP2011503115A (ja) 2007-11-15 2011-01-27 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Ｎ含有複素環式化合物
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS RN 913517-57-4、外15種，REGISTRY（STN）[online]，2006年11月17日，（発行日は最も遅いものに基づく）[検索日 2023.07.11]

Also Published As

Publication number Publication date
IL281811B2 (en) 2025-03-01
JP2022508523A (ja) 2022-01-19
US11098056B2 (en) 2021-08-24
MX2021003794A (es) 2021-09-08
BR112021005914A2 (pt) 2021-06-29
AU2019355870B2 (en) 2023-11-16
SG11202102987VA (en) 2021-04-29
MA53043A1 (fr) 2022-08-31
TW202035419A (zh) 2020-10-01
IL281811A (en) 2021-05-31
EP3861000A1 (en) 2021-08-11
KR20210087033A (ko) 2021-07-09
AU2019355870A1 (en) 2021-05-20
CA3114722A1 (en) 2020-04-09
IL281811B1 (en) 2024-11-01
MA53043B2 (fr) 2024-05-31
CN113423711B (zh) 2024-03-15
KR102903997B1 (ko) 2025-12-26
US20200102324A1 (en) 2020-04-02
WO2020072504A1 (en) 2020-04-09
TWI821426B (zh) 2023-11-11
CN113423711A (zh) 2021-09-21
CO2021005738A2 (es) 2021-05-10

Similar Documents

Publication Publication Date Title
US11542266B1 (en) Substituted piperidines as BTK inhibitors
US9273057B2 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
KR20250024842A (ko) 아자퀴나졸린 범-kras 억제제
EP4549438A1 (en) Five-membered and six-membered nitrogen-containing compound, and intermediate, preparation method and use thereof
KR20230028269A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
EP3546458B1 (en) ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer
US20240342292A1 (en) Compounds for the Degradation of EGFR Kinase
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
WO2024192064A1 (en) Compounds and compositions as smarca2/4 degraders and uses thereof
EP4069366B1 (en) Atm kinase inhibitors and compositions and methods of use thereof
JP7545979B2 (ja) ＵＤＰグリコシルトランスフェラーゼ阻害剤としてのチエノ［３，２－ｂ］ピリジン誘導体および使用の方法
RU2810928C2 (ru) Ингибиторы уридин-5-дифосфат (udp) гликозилтрансферазы и способы их применения
HK40082036B (en) Atm kinase inhibitors and compositions and methods of use thereof
HK40082036A (en) Atm kinase inhibitors and compositions and methods of use thereof
HK40053673B (zh) 一种btk抑制剂环衍生物及其制备方法和药学上的应用
HK40043697A (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240826

R150 Certificate of patent or registration of utility model

Ref document number: 7545979

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150